Author

Eun Hee Jung

Seoul National UniversityORCID 0000-0002-3057-4502Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Jee Hyun KimiD· 2 shared Jin Won KimiD· 2 shared Koung Jin SuhiD· 2 shared Kui‐Jin KimiD· 2 shared Se Hyun KimiD· 2 shared Yu Jung KimiD· 2 shared Andrew J. AguirreiD· 1 shared Bo‐Ram ParkiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jee Hyun KimORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Loss of p21-activated kinase 4 (PAK4) suppresses pancreatic tumor progression and metastasis through regulating E-cadherin

Kui‐Jin Kim, Cheng Hyun Lee, Hee Young Na, Ji Hea Sung, Bo‐Ram Park, Sung-Hyun Hwang, Woochan Park, 서정민, Minsu Kang, Eun Hee Jung, Sang‐A Kim, Koung Jin Suh, Ji Yun Lee, Se Hyun Kim, Jeong-Ok Lee, , Jin Won Kim

This study shows that PAK4 promotes pancreatic cancer metastasis by reducing E-cadherin, and its loss inhibits tumor progression and metastasis.

Cancer Gene Therapy · Oct 31, 2026Peer-reviewedCancer Biology

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

Sung‐Hyun Hwang, Mingyun Bae, Ji‐Won Kim, Seung Yoon Hyun, Kui‐Jin Kim, Joshua H. Choe, Min Jung Kim, Ji Won Park, Seung‐Yong Jeong, Songji Choi, Woochan Park, Jeongmin Seo, Heejung Chae, Min-Su Kang, Eun Hee Jung, , Keun‐Wook Lee

This paper identifies VEGFA-VEGFR2 signaling driven by PI3Kγ activation as a mechanism of acquired resistance to KRAS G12D inhibitors and shows that blocking this pathway restores drug sensitivity in resistant cancer models.

bioRxiv · Sep 16, 2025 · PreprintCancer Biology